HK1052872A1 - 微团 - Google Patents

微团 Download PDF

Info

Publication number
HK1052872A1
HK1052872A1 HK03105085.2A HK03105085A HK1052872A1 HK 1052872 A1 HK1052872 A1 HK 1052872A1 HK 03105085 A HK03105085 A HK 03105085A HK 1052872 A1 HK1052872 A1 HK 1052872A1
Authority
HK
Hong Kong
Prior art keywords
micelles
pharmaceutical compositions
stereoisomers
compound
methods
Prior art date
Application number
HK03105085.2A
Other languages
English (en)
Chinese (zh)
Inventor
Mcshane James
Arens Tori
Kaneko Kazuhiro
Watanabe Tomohiro
Ashizawa Kazuhide
Original Assignee
Eisai R&D Management Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co., Ltd. filed Critical Eisai R&D Management Co., Ltd.
Publication of HK1052872A1 publication Critical patent/HK1052872A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK03105085.2A 2000-02-18 2001-02-20 微团 HK1052872A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18376800P 2000-02-18 2000-02-18
US60/183,768 2000-02-18
PCT/US2001/005297 WO2001060382A1 (en) 2000-02-18 2001-02-20 Micelles

Publications (1)

Publication Number Publication Date
HK1052872A1 true HK1052872A1 (zh) 2003-10-03

Family

ID=22674206

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03105085.2A HK1052872A1 (zh) 2000-02-18 2001-02-20 微团

Country Status (10)

Country Link
US (3) US6906042B2 (enExample)
EP (2) EP2452684B1 (enExample)
JP (2) JP4959085B2 (enExample)
KR (1) KR100841813B1 (enExample)
AU (2) AU2001238507C9 (enExample)
CA (1) CA2400371C (enExample)
ES (1) ES2664818T3 (enExample)
HK (1) HK1052872A1 (enExample)
IL (2) IL151314A0 (enExample)
WO (1) WO2001060382A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030130212A1 (en) * 1999-01-14 2003-07-10 Rossignol Daniel P. Administration of an anti-endotoxin drug by intravenous infusion
AU2001238507C9 (en) * 2000-02-18 2005-07-07 Eisai R&D Management Co., Ltd. Micelles
JP4366081B2 (ja) * 2001-05-22 2009-11-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 高度に精製されたアンチエンドトキシン化合物
US7727974B2 (en) 2001-08-10 2010-06-01 Eisai R & D Management Co., Ltd. Methods of reducing the severity of mucositis
WO2003013440A2 (en) * 2001-08-10 2003-02-20 Eisai Co., Ltd. Treatment and prevention of heat shock protein-associated diseases and conditions
WO2003082303A1 (en) * 2002-03-29 2003-10-09 Wisconsin Alumni Research Foundation Polymeric micelle formulations of hydrophobic compounds and methods
WO2004034992A2 (en) * 2002-10-15 2004-04-29 Wisconsin Alumni Research Foundation Encapsulation and deaggregation of polyene antibiotics using poly(ethylene glycol)-phospholipid micelles
CA2536283A1 (en) * 2003-08-20 2005-03-03 Ajinomoto Co., Inc. Pharmaceutical preparations having an improved solubility
ATE446581T1 (de) * 2004-03-12 2009-11-15 Trinity College Dublin Magnetoresistives medium
WO2007026675A1 (ja) * 2005-08-31 2007-03-08 Eisai R & D Management Co., Ltd. リピッドａ類縁体の製造方法
US20070249572A1 (en) * 2005-12-20 2007-10-25 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070178049A1 (en) * 2005-12-20 2007-08-02 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070197486A1 (en) * 2005-12-20 2007-08-23 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids
US20070160542A1 (en) * 2005-12-20 2007-07-12 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070185066A1 (en) * 2005-12-20 2007-08-09 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
JP2009526619A (ja) * 2006-02-15 2009-07-23 ティカ レーケメデル アーベー 質量減量を伴うコルチコステロイドの滅菌
BR112014024139A8 (pt) 2012-03-28 2018-01-16 Univ Maryland administração de eritoran ou sais farmaceuticamente aceitáveis do mesmo para tratar infecções de ortomixovírus
WO2018053073A1 (en) 2016-09-16 2018-03-22 Eisai R&D Management Co., Ltd. Method of use of eritoran as a tlr4 antagonist for treatment of ebola and marburg disease
BR112021010717A2 (pt) 2018-12-17 2021-08-31 Eisai R&D Management Co., Ltd. Formulação que compreende lipossomas
US11198831B2 (en) 2019-01-31 2021-12-14 Kvi Llc Lubricant for a device
WO2021207218A1 (en) 2020-04-06 2021-10-14 Eisai R&D Management Co., Ltd. Treatment of nidovirales infection with eritoran

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530113A (en) 1991-10-11 1996-06-25 Eisai Co., Ltd. Anti-endotoxin compounds
US6417172B1 (en) 1995-06-05 2002-07-09 Eisai Co., Ltd. Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs
US5681824A (en) 1995-06-05 1997-10-28 Eisai Co., Ltd. Substituted liposaccharides useful in the treatment and prevention of endotoxemia
AU7254396A (en) * 1995-09-29 1997-04-17 Eisai Research Institute Method for treating alcoholic liver disease
JP4326030B2 (ja) * 1996-07-03 2009-09-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 リピッドａ類縁体含有注射用製剤及びその製造方法
US6235724B1 (en) * 1996-07-03 2001-05-22 Eisai Co., Ltd. Injections containing lipid a analogues and process for the preparation thereof
US6495532B1 (en) 1997-03-19 2002-12-17 Sky High, Llc Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof
JP2002501540A (ja) 1997-05-23 2002-01-15 エーザイ株式会社 製薬製剤を調製するための方法
US6437006B1 (en) 1999-09-27 2002-08-20 American Cyanamid Company Pharmaceutical carrier formulation
EP1250141A4 (en) 2000-01-14 2007-05-16 Eisai Co Ltd Prevention and treatment of endotoxemia and related complications in the field of surgery
AU2001238507C9 (en) 2000-02-18 2005-07-07 Eisai R&D Management Co., Ltd. Micelles
US6861512B2 (en) 2000-03-01 2005-03-01 Eisai Co., Ltd. Separation of olefinic isomers
US20030105033A1 (en) 2000-06-09 2003-06-05 Rossignol Daniel P. Administration of an anti-endotoxin drug by bolus or intermittent intravenous infusion
JP4179881B2 (ja) 2000-12-06 2008-11-12 エーザイ株式会社 凍結乾燥ケークの抵抗を測定するためのシステム及び方法
WO2002089743A2 (en) 2001-05-09 2002-11-14 The Regents Of The University Of Michigan Use of compositions for treating rosacea
US7727974B2 (en) 2001-08-10 2010-06-01 Eisai R & D Management Co., Ltd. Methods of reducing the severity of mucositis
AU2004218358A1 (en) 2003-03-05 2004-09-16 Eisai R&D Management Co., Ltd. Compositions and methods for preventing and treating endotoxin-related diseases and conditions

Also Published As

Publication number Publication date
AU2001238507B2 (en) 2004-04-22
AU2001238507C1 (en) 2005-02-24
WO2001060382A1 (en) 2001-08-23
JP2012116860A (ja) 2012-06-21
EP2452684B1 (en) 2018-01-24
US6906042B2 (en) 2005-06-14
IL151314A (en) 2007-06-03
CA2400371A1 (en) 2001-08-23
US7989432B2 (en) 2011-08-02
EP1274443B1 (en) 2017-05-10
KR100841813B1 (ko) 2008-06-26
US20030216331A1 (en) 2003-11-20
KR20030011774A (ko) 2003-02-11
JP2003522797A (ja) 2003-07-29
AU2001238507C9 (en) 2005-07-07
US20050181039A1 (en) 2005-08-18
ES2664818T3 (es) 2018-04-23
EP2452684A3 (en) 2012-10-03
US7390793B2 (en) 2008-06-24
JP4959085B2 (ja) 2012-06-20
AU3850701A (en) 2001-08-27
EP2452684A2 (en) 2012-05-16
EP1274443A1 (en) 2003-01-15
IL151314A0 (en) 2003-04-10
US20090136564A1 (en) 2009-05-28
EP1274443A4 (en) 2008-12-31
CA2400371C (en) 2009-12-08

Similar Documents

Publication Publication Date Title
HK1052872A1 (zh) 微团
EP1040823A3 (en) Stable foam compositions
WO2001042219A3 (en) Novel substituted phenanthridinones and methods of use thereof
CA2123160A1 (en) Controlled release formulation
HUP0004050A3 (en) Itraconazole exhibiting improved solubility, a method of preparing the same and pharmaceutical composition for oral administration comprising the same
CA2427815A1 (en) Controlled release hydrocodone formulations
SI1417206T1 (sl) Novi H piridazin onski derivati farmacevtski sestavki ki jih vsebujejo in postopek za pripravo aktivne sestavine
AU2002346973A1 (en) Oral Dosage Form for Propiverine or its Pharmaceutically Acceptable Salts with an Extended Release of the Active Ingredient
CA2295035A1 (en) Pharmaceutical formulations containing voriconazole
AU2002255077A1 (en) Derivatives of N-(arylsulfonyl)beta-aminoacids comprising a substituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing same
AU2002239282A1 (en) Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
WO2001027111A3 (de) Bicyclische imidazo-3-yl-aminderivate
AU2001269198A1 (en) Novel 1,3-dihydro-2h-indol-one derivatives, method for preparing same and pharmaceutical compositions containing them
CA2380087A1 (en) Beta-carboline drug products
CA2419314A1 (en) Preparation of risperidone
WO2001027110A3 (de) Am sechsring substituierte, bicyclische imidazo-3-yl-aminderivate
EP2017269A3 (en) A pharmaceutical compodition comprising form II crystalline Ritonavir and a preparation thereof
AU2002234545A1 (en) Pharmaceutical preparation in the form of a suspension comprising an acid-labileactive ingredient
WO2002032901A3 (en) Bridged piperazine derivatives
EP1900741A8 (en) New process for the production of oxabispidines
HUP0102631A3 (en) 1,1- and 1,2-disubstituted cyclopropane derivatives, process for their preparation and pharmaceutical compositions containing them
CA2399709A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid and/or physiologically compatible salts thereof for producing a medicament for treating cancers
CA2376847A1 (en) Complex of eletriptan and a cyclodextrin derivative
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
HUP0204111A3 (en) Novel process for the preparation of alpha-(2,4-disulfophenyl)-n-tert-butylnitrone and pharmaceutically acceptable salts thereof